Pulmonary langerhans cell histiocytosis-associated pulmonary hypertension: Clinical characteristics and impact of pulmonary arterial hypertension therapies

Chest

Volumn 142, Issue 5, 2012, Pages 1150-1157

  Le Pavec, Jérôme ^a   Lorillon, Gwenaël ^a   Jaïs, Xavier ^b,c,d   Tcherakian, Colas ^e   Feuillet, Séverine ^a   Dorfmüller, Peter ^b,d,f   Simonneau, Gérald ^b,c,d   Humbert, Marc ^b,c,d   Tazi, Abdellatif ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d Universite Paris Sud   (France)

^e FOCH HOSPITAL   (France)

^f CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEART INDEX; HUMAN; LANGERHANS CELL HISTIOCYTOSIS; LUNG ARTERY PRESSURE; LUNG DISEASE; LUNG VASCULAR RESISTANCE; MALE; MORTALITY; PHYSICAL CAPACITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY LANGERHANS CELL HISTIOCYTOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 84865611511     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2490     Document Type: Article

References (31)

1. Abbott GF, Rosado-de-Christenson ML, Franks TJ, Frazier AA, Galvin JR. From the archives of the AFIP: pulmonary Langerhans cell histiocytosis. Radiographics. 2004;24(3):821-841. (Pubitemid 38703247)
2. Sundar KM, Gosselin MV, Chung HL, Cahill BC. Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, radiology, and clinical evolution of disease. Chest. 2003;123(5):1673-1683. (Pubitemid 36549791)
3. Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. 2006;27(6):1272-1285. (Pubitemid 44914314)
4. Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med. 2000;342(26):1969-1978. (Pubitemid 30419093)
5. Basset F, Corrin B, Spencer H, et al. Pulmonary histiocytosis X. Am Rev Respir Dis. 1978;118(5):811-820. (Pubitemid 9066033)
6. Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord. Eur Respir J. 1996;9(10):2002-2006.
7. Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 2002;346(7):484-490. (Pubitemid 34441739)
8. Dauriat G, Mal H, Thabut G, et al. Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis. Transplantation. 2006;81(5):746-750.
9. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med. 2000;161(1):216-223. (Pubitemid 30055928)
10. Harari S, Simonneau G, De Juli E, et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant. 1997;16(4):460-463. (Pubitemid 27199604)
11. Chaowalit N, Pellikka PA, Decker PA, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc. 2004;79(10):1269-1275. (Pubitemid 39299072)
12. Harari S, Brenot F, Barberis M, Simmoneau G. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest. 1997;111(4):1142-1144.
13. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension . J Am Coll Cardiol. 2009;54(suppl 1):S78-S84.
14. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919-923.
15. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S43-S54.
16. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16 :1-100.
17. Brauner MW, Grenier P, Tijani K, Battesti JP, Valeyre D. Pulmonary Langerhans cell histiocytosis: evolution of lesions on CT scans. Radiology. 1997;204(2):497-502. (Pubitemid 27337502)
18. Weitzenblum E, Chaouat A, Canuet M, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med. 2009;30(4):458-470.
19. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
20. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-223. (Pubitemid 17137857)
21. Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant. 2010;29(2):181-187.
22. Benyounes B, Crestani B, Couvelard A, Vissuzaine C, Aubier M. Steroid-responsive pulmonary hypertension in a patient with Langerhans' cell granulomatosis (histiocytosis X). Chest. 1996;110(1):284-286. (Pubitemid 26249339)
23. Hamada K, Teramoto S, Narita N, Yamada E, Teramoto K, Kobzik L. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J. 2000;15(2):421-423. (Pubitemid 30085976)
24. Kiakouama L, Cottin V, Etienne-Mastroïanni B, Khouatra C, Humbert M, Cordier JF. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. Eur Respir J. 2010;36(1):202-204.
25. Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med. 1981;304(26):1582-1585. (Pubitemid 11122507)
26. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006;61(1):68-74. (Pubitemid 43106981)
27. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):189-194. (Pubitemid 40981192)
28. Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J. 2012;40(3):630-640.
29. Galiè N, Hoeper MM, Humbert M, et al ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493-2537.
30. Colby TV, Lombard C. Histiocytosis X in the lung. Hum Pathol. 1983;14(10):847-856. (Pubitemid 13015025)
31. Travis WD, Borok Z, Roum JH, et al. Pulmonary Langerhans cell granulomatosis (histiocytosis X). A clinicopathologic study of 48 cases. Am J Surg Pathol. 1993;17(10):971-986. (Pubitemid 23289339)